Drug Trial Radar · NCT05317312
Study of MR-107A-02 in the Treatment of Post Surgical Dental Pain.
Last checked: Nov 20, 2026Latest source record: Aug 7, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
111
Actual
Start
Mar 31, 2022
Primary completion
Jun 15, 2022
Study completion Jun 20, 2022
Sponsor
- Lead sponsor
- Mylan Specialty, LPIndustry
- Sponsor type
- Industry
- First posted
- Apr 7, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
MR-107A-02 is being studied to investigate its efficacy, safety and dose-response after dental surgery.
Conditions
- Acute Pain
- Post Operative Pain
- Pain
Interventions
MR-107A-02Drug
MR-107A-02 oral tablet
PlaceboDrug
Placebo oral tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Summed Pain Intensity Difference (SPID)Time frame: 24 hours after the first dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Research Facility 201
Salt Lake City, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.